STRM.BIO is a biotechnology company developing a non-viral, cell-derived delivery modality that enables safe, targeted, and scalable in vivo delivery of complex genetic payloads. Our megakaryocyte-derived vesicle (MV) platform is designed to address the limitations of traditional viral and synthetic delivery systems, unlocking new therapeutic opportunities across gene editing, RNA therapeutics, and immune cell engineering. Our pipeline includes programs focused on rare hematological diseases such as Fanconi Anemia and in vivo CAR-T therapy.